Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.43 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.39 |
| ▸ | RECQL | P46063 | 1/20 | 0.38 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.35 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3072798 | 1.00 | ALDH1A1 (0.43) | ALDH1A1CHRM1RECQLHCRTR2MEN1 | |
| SCHEMBL3072590 | 1.00 | ALDH1A1 (0.43) | ALDH1A1CHRM1RECQLHCRTR2MEN1 | |
| SCHEMBL581403 | 0.91 | SMN1; SMN2 (0.38) | ALDH1A1MEN1KMT2AKDM4EOPRK1 | |
| SCHEMBL581402 | 0.91 | SMN1; SMN2 (0.38) | ALDH1A1MEN1KMT2AKDM4EOPRK1 | |
| SCHEMBL3069685 | 0.91 | SMN1; SMN2 (0.38) | ALDH1A1MEN1KMT2AKDM4EOPRK1 | |
| SCHEMBL581047 | 0.90 | ALDH1A1 (0.35) | ALDH1A1CHRM1RECQLHCRTR2MEN1 | |
| SCHEMBL3074921 | 0.90 | ALDH1A1 (0.35) | ALDH1A1CHRM1RECQLHCRTR2MEN1 | |
| SCHEMBL3078762 | 0.90 | ALDH1A1 (0.35) | ALDH1A1CHRM1RECQLHCRTR2MEN1 | |
| SCHEMBL581628 | 0.90 | EPHX2 (0.44) | ALDH1A1HCRTR2MEN1MAPK1HTT | |
| SCHEMBL580925 | 0.89 | KMT2A (0.43) | ALDH1A1CHRM1MEN1MAPK1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8415378-B2 | Isoxazol-3(2H)-one analogs as therapeutic agents | ASTRAZENECA AB (SE) | 2013-04-09 | — | — | US | disclosed |
| EP-2417131-A1 | ISOXAZOL-3(2H)-ONE ANALOGS AS THERAPEUTIC AGENTS | AstraZeneca AB (SE) | 2012-02-15 | — | — | EP | disclosed |
| WO-2010117323-A1 | METHOD AND APPARATUS FOR PRODUCING HEAT ENERGY AND CARBON DIOXIDE | ASTRAZENECA AB (SE) | 2010-10-14 | — | — | WO | disclosed |
| US-20100261755-A1 | ISOXAZOL-3(2H)-ONE ANALOGS AS THERAPEUTIC AGENTS | ASTRAZENECA AB (SE) | 2010-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100261755-A1 | ISOXAZOL-3(2H)-ONE ANALOGS AS THERAPEUTIC AGENTS | NR4A3, CBR3, OXER1 | ALDH1A1 2598/4885CHRM1 291/4885RECQL 3028/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.